Journal
BREAST
Volume 24, Issue 1, Pages 18-23Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2014.10.008
Keywords
Locally advanced breast cancer (LABC); Inflammatory breast cancer; Pathologic complete response (pCR); Human epidermal growth factor receptor 2 (HER2); Triple-negative breast cancer (TNBC); Carboplatin
Categories
Funding
- [P30 CA 33572]
Ask authors/readers for more resources
Background: Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2(+) and triple-negative breast cancers (TNBC) may increase pCR rates. Methods: Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed. Results: Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR. Conclusions: Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available